drugset / Trial / NCT01579383

Safety Tolerability and Pharmacokinetics of ALD403

NCT01579383

Phase 1 Completed 104 enrolled Alder Biopharmaceuticals, Inc.
RandomizedSingle-groupTriple-blindTreatment

Summary

The purpose of this study is to determine the safety, tolerability and pharmacokinetics of ALD403, a monoclonal antibody, administered by intravenous infusion and subcutaneous injection.

Timeline

Start
2012-04
Primary completion
2012-12
Completion
2013-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Eptinezumab Monoclonal antibody Intravenous
Subject Sumatriptan Unknown Subcutaneous

Indications